The ALS Association will host an international scientific workshop, “Drug Discovery for ALS: Opportunities and Challenges,” in Washington, D.C., March 4 – 7, 2012. More than 130 people whose organizations specialize in ALS research and related fields will attend this event. Participants include those from government agencies such as the Food and Drug Administration and The National Institute of Neurological Disorders and Stroke (NINDS). Other attendees consist of individuals from global biotech firms, academic institutions and non-profit organizations committed to ALS research and related disorder.
The goal of this international workshop is to identify key barriers and enablers for translating findings in basic research into the clinic for ALS. It is an opportunity for clinical and scientific leaders in industry and academia in neurodegeneration to share their findings and discuss the future directions and opportunities for ALS drug discovery. This workshop also provides an opportunity for academic scientists new to the field of drug discovery to have a global vision on drug development and to learn how basic research can be translated into a marketable drug.
This three-day workshop begins with a keynote address from Chris Austin of the National Institutes of Health. Austin will discuss ALS translational research opportunities at NIH.
Other highlights from the conference include:
Along with The ALS Association, the following organizations are sponsoring the workshop: The ALS Society of Canada, the ALS Association Greater Philadelphia Chapter, The Alan Phillips Discovery Awards, Biogen, Bristol Myers Squibb, Cytokinetics, Isis, Knopp, NINDS and Pfizer.
Detailed information about this event will be available on our Website after the conference concludes.